ENANTA PHARMACEUTICALS INC (ENTA) Form 10-Q — Aug 12, 2026

Key figures

Eps

-$0.67 (Q3 basic and diluted); -$1.54 (nine months)

Revenue

$14.4 million (Q3 FY2026, quarter ended June 30, 2026)

Net Income

-$19.5 million (Q3); -$44.5 million (nine months)

Revenue Yoy

-$4.0 million YoY per filing (from $18.3 million), attributed to AbbVie's lower reported HCV sales

Total Assets

$296.9 million

Cash Position

$211.5 million in cash, cash equivalents and short/long-term marketable securities ($33.4 million cash and equivalents)

Shares Outstanding

29125402

Cash Runway

into fiscal 2029

Atm Facility

$75.0 million with Jefferies LLC (July 2, 2026; no shares sold through filing date)

Ga Expense Q3

$9.5 million

Rd Expense Q3

$22.1 million (vs $27.2 million prior year)

Nine Month Net Loss

$44.5 million (vs $63.2 million prior year)

Nine Month Revenue

$50.1 million (vs $50.2 million prior year)

Interest Expense Q3

$4.1 million (vs $1.6 million prior year, driven by OMERS royalty-sale liability)

Accumulated Deficit

$449.5 million

Prior Year Q3 Net Loss

$18.3 million (-$0.85 per share)

Prior Year Q3 Revenue

$18.3 million

Stockholders Equity

$101.1 million

October2025 Offering

7,475,000 shares at $10.00; $74.75 million gross proceeds

Weighted Avg Shares Q3

29.09 million

Royalty Retained Share

45.5% of MAVYRET/MAVIRET royalties through June 30, 2032

Royalty Sale Liability

$125.1 million owed to OMERS at June 30, 2026

Rsv Market Opportunity

over $2 billion (company estimate)

Abvie Cumulative Payments

approximately $1.372 billion through June 30, 2026

Omers Imputed Interest Rate

12.8% effective annual

Price after filing

Close on the filing date to close N calendar days later (from $13.50). Historical, not a forecast.